ET 01
Alternative Names: BCL11A enhancer modified autologous haematopoietic stem cells; ET-01 - EdiGeneLatest Information Update: 15 Apr 2025
At a glance
- Originator EdiGene Inc
- Class Gene therapies; Haematopoietic stem cells therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Fetal haemoglobin expression stimulants; Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia; Beta-thalassaemia
Most Recent Events
- 30 Mar 2025 EdiGene terminates Phase-I clinical trials in Beta-thalassaemia (In children, In adolescents, In adults) in China (IV) (NCT04925206)
- 28 Mar 2025 No recent reports of development identified for research development in Anaemia in China (IV)
- 12 Mar 2025 EdiGene terminates a Phase-I clinical trials in Beta-thalassaemia (In children, In adolescents, In adults) in China (IV) due to change in development plan (NCT04390971)